The Information in this section is intended for healthcare professionals only.

Please confirm that you are a healthcare professional.

The Information in this section is intended for healthcare professionals only.

Please confirm that you are a healthcare professional.


This site uses cookies for site interaction analysis with a purpose of service quality enhancing and uninterrupted site work. More details in Cookies Policy
11 January 2024

Darnytsia Is to Bring More Than Fifty New Medicines to the Market over the Next Three Years

11 January 2024

Pharmaceutical Company ‘Darnytsia’ plans to release fifty-six brands of new medicines by 2027. Forty-five of these will be brands of their own production, and eleven will be released under licensing conditions.

Today, both original and generic medicines are represented in the Darnytsia portfolio. Recall that generic medicines have the same active pharmaceutical ingredient as the original innovative medicines.

Generics are designed to make modern, effective, safe, and high-quality medicines available to patients, and original products open up additional opportunities in treatment, meeting new medical needs.

As a manufacturer of generic and original medicinal products, Darnytsia has experience in conducting not only clinical studies of bioequivalence of generics, but also all phases of clinical trials required to prove the effectiveness and safety of original products.

Despite the full-scale war, Darnytsia is developing two projects on clinical development of new products with the involvement of reputable international partners. More than fifteen new medicine clinical development projects are scheduled for the next three years.

‘Over the past five years, we have completed twelve clinical trials, ten of which were bioequivalence studies for generics. At the same time, we involved service providers from other countries in eleven out of twelve projects. The choice of service providers for clinical trials is an important prerequisite for the quality of the studies conducted and the reliability of their results’, Andrii Doroshenko, Head of the Clinical Research and Monitoring Department of Pharmaceutical Company ‘Darnytsia’, says.

In the near future, Darnytsia will focus mainly on the production of cardiovascular, analgesic, antidiabetic, antibacterial medicines, as well as medicines for the treatment of neuropsychiatric diseases, in particular post-traumatic stress disorder (PTSD) and depression.

‘We have a finger on the pulse, providing Ukrainians with the medicines they need today. Our market share is increasing not only due to the launch of new products on the market, but also due to the fact that more and more Ukrainians prefer high-quality and affordable medicines of domestic production’, Inna Deniak, Business Development Director of Pharmaceutical Company ‘Darnytsia’, says.

Specialized edition for medical institutions and doctors.